Clinical trial NCT02895815: Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
Official title: A Phase 2, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Subretinal Administration of CNTO 2476 in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Visual Acuity
Geographic Atrophy
Macular Degeneration
Lead sponsor: Janssen Pharmaceutical K.K.
Sponsor class: INDUSTRY
First posted: 2016-09-12
Enrollment: 0
Sex: ALL
Minimum age (years): 50
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate the efficacy and safety of CNTO 2476 cells administered into the subretinal space by the suprachoroidal surgical approach and the subretinal access kit (SRAK-02) in participants with visual acuity impairment associated with Geographic Atrophy (GA) secondary to Age Related Macular Degeneration (AMD).

Detailed description: This is a Phase 2 study to evaluate the efficacy and safety of a single subretinal administration of CNTO 2476 compared with the untreated control group, as well as to assess the safety and usability profile of the procedure and the device for cell therapy delivery in participants with visual acuity impairment associated with Geographic Atrophy (GA) secondary to Age Related Macular Degeneration (AMD). The duration of participation in the study for each participant is approximately 3 years. Efficacy will be evaluated at 6 month, 12 months and every 6 month thereafter. Participant's safety will be monitored throughout the study.

Eligibility criteria: Inclusion Criteria:

* Participant is a suitable candidate for ophthalmologic surgery, is willing and able to comply with the surgical procedure, scheduled visits, treatment plan, laboratory tests and other study procedures. Participant has met criteria of the surgery center anti coagulation protocol, if applicable
* Confirmed diagnosis of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) confirmed within 28 days prior to initial randomization by the central reading center using fundus photographs and including the following; a) The study eyes must have at least 1 GA lesion that involves the fovea, and a Macular Photocoagulation Study (MPS) disc areas (DA) of \>= 1 and \<= 7 (1 Macular Photocoagulation Study Disc Area (MPS DA equivalent to 2.54 millimeter (mm)\^2 on the retina) determined by screening images of fundus autofluorescence photographs as calculated by the reading center. If GA is multifocal, at least 1 lesion must be \>= 0.5 DA, b) GA must be able to be photographed in its entirety and may be contiguous with peripapillary atrophy, c) Retinal photographs, fundus autofluorescence images, and angiography of sufficient quality, allowing assessment of the macular area according to standard clinical practice, can be obtained d) The imaging center must be able to delineate and confirm peripapillary atrophy with fundus photography and fundus autofluorescence, e) Images must include the central field 1, 2, and 3 field images as defined by the University of Wisconsin standards as well as a supero temporal image to capture the subretinal injection area if possible
* Female participants must be postmenopausal with last menses 12 months prior, or longer without medical reasons (example, treatment with a drug), or a measured follicle stimulating hormone \>= 26 milli-international units per milliliter (mIU/mL)
* Study eyes will have a best corrected visual acuity (BCVA) of 20/80 to 20/800 (Early Treatment Diabetic Retinopathy Study (ETDRS) logMAR value 0.6-1.6). BCVA in the study eye must be worse than the BCVA in the fellow eye at screening
* Male participants must be sterile or willing to use 2 approved methods of contraception from first day postoperatively to 3 months postoperatively

Exclusion Criteria:

* Participant has a history of neovascular ("wet") AMD in the study eye, including any evidence of retinal pigment epithelium rips or evidence of subretinal or choroidal neovascularization. History or evidence of neovascular AMD in the fellow eye is allowed, if antivascular endothelial growth factor (VEGF) therapy has not been required for at least 8 weeks prior to screening
* A diagnosis of glaucoma with an intraocular pressure (IOP) \>= 25 millimeter of mercury (mm Hg) while being treated with an ocular hypotensive drug. Treatment should be no more than 1 drug preparation/combination, which can contain 1 or 2 ocular hypotensive active ingredients; participants receiving more than 2 ocular hypotensive active ingredients are excluded
* Nuclear sclerotic cataract, cortical spoking, posterior subcapsular cataract above Grade 2 per Age Related Eye Disease Study (AREDS) scale or any other ophthalmologic condition that reduces the clarity of the media that, in the opinion of the investigator or reading center, interferes with ophthalmologic examination (example, corneal abnormalities, inadequate pupillary dilation)
* Myopia \>-8 diopters and participants with \>4 diopters of astigmatism, and \>+10 diopters of hyperopia
* Previous vitrectomy, retinal detachment repair, submacular surgery, other surgical interventions targeting AMD, scleral buckling or glaucoma filtration surgery or any other extraocular or orbital procedure in the study eye that, in the opinion of the surgeon, would hamper the suprachoroidal cannulation procedure in the study eye

Primary outcomes:
measure: Percentage of Participants Showing Improvement From Baseline of Greater Than or Equal to (>=) 15 Letters in Best Corrected Visual Acuity (BCVA) at Month 6
timeFrame: Month 6
Secondary outcomes:
measure: Percentage of Participants Showing Improvement >=15 BCVA Letters From Baseline at 12 Month
timeFrame: Baseline and Month 12
measure: Percentage of Participants Losing >=15 Best Corrected Visual Acuity (BCVA) Letters From Baseline at 6 and 12 Months
timeFrame: Baseline, Month 6 and 12
measure: Change in Mean Number of BCVA Letters From Baseline at 6 and 12 Months
timeFrame: Baseline, Month 6 and 12
measure: Change in Growth Rate of Geographic Atrophy (GA) Lesion Documented at Baseline to 6 and 12 Months
timeFrame: Baseline, Month 6 and 12
measure: Mean Change in Reading Acuity (RA) From baseline to 6 and 12 Months
timeFrame: Baseline, Month 6 and 12
measure: Mean Change in Maximum Reading Speed (MRS) From Baseline to 6 and 12 Months
timeFrame: Baseline, Month 6 and 12
measure: Mean Change in Critical Print Size (CPS) From Baseline to 6 and 12 Months
timeFrame: Baseline, Month 6 and 12
measure: Mean Change in Low Luminance Best Corrected Visual Acuity (LL BCVA) Letters From Baseline to 6 and 12 Months
timeFrame: Baseline, Month 6 and 12
measure: Percentage of Participants With Gain of >= 15 Letters in LL BCVA From Baseline to 6 and 12 Months
timeFrame: Baseline, Month 6 and 12
measure: Mean Change in Contrast Sensitivity From Baseline to 6 and 12 Months
timeFrame: Baseline, Month 6 and 12
measure: Number of Participants With Significant Changes in Retinal Morphology
timeFrame: Baseline, Month 6 and 12
measure: Percentage of Participants who Convert to Neovascular Age-Related Macular Degeneration (AMD) in the Study Eye and in the Fellow Eye
timeFrame: Baseline, Month 6 and 12
measure: Percentage of Participants who Achieved Technical Success in the Active Drug Group
timeFrame: 6 Months
measure: Percentage of Participants who Achieved Procedural Success in the Active Drug Group
timeFrame: Month 6 and 12
measure: Number of Participants with Ocular Adverse Events (AEs) and Serious Adverse Events (SAEs)
timeFrame: Up to Long term Follow up (Month 36)
measure: Mean Change From Baseline at 6 and 12 Months in Participants Reported Health-Related Quality of Life as Assessed by Short Form (36) Health Survey
timeFrame: Baseline, Month 6 and 12
measure: Mean Change From Baseline at 6 and 12 Months in Participants Reported Health Related Quality of Life as Assessed by Functional Reading Index Questionnaire (FRI)
timeFrame: Baseline, Month 6 and 12
measure: Incidence of Anti-CNTO 2476 Antibodies
timeFrame: Baseline, Day 7 and 15, Month 2, 3 and 6
measure: Mean Change From Baseline at 6 and 12 Months in Participants Reported Health-Related Quality of Life as Assessed by National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) Score
timeFrame: Baseline, Month 6 and 12
measure: Mean Change From Baseline at 6 and 12 Months in Participants Reported Health-Related Quality of Life as Assessed by Near Vision Subscale Score
timeFrame: Baseline, Month 6 and 12
Other outcomes:
Locations:
Study officials:
affiliation: Janssen Pharmaceutical K.K.
name: Janssen Pharmaceutical K.K., Japan Clinical Trial
role: STUDY_DIRECTOR
References: